Overall rank by patents
#49,962
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Regenerx Biopharmaceuticals, Inc.
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, active 2015–2018. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
5
Total patents granted
3
CPC technology areas
14.0
Avg claims per patent
-100%
5-year filing velocity
The verdict
Regenerx holds 5 US patents across 3 technology areas, rank #49,962 of 50,000 tracked assignees.
- #49,962
- of 50,000 US assignees by volume
- Top 93%
- by Innovation Score (20.7/100)
- 14.0
- avg claims per patent
- -100%
- filing velocity, last 5 yrs
Portfolio overview
Regenerx Biopharmaceuticals, Inc. has been granted 5 US utility patents between 2015 and 2018, placing Regenerx Biopharmaceuticals, Inc. at rank #49,962 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.0 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Regenerx Biopharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Regenerx sits between RED BOX Recorders Limited (5 patents, rank #49,958) and REL, Inc. (5 patents, rank #49,966) - the closest US assignees by grant volume. The composite Innovation Score of 20.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 5 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Regenerx Biopharmaceuticals, Inc.'s 14.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Regenerx Biopharmaceuticals, Inc. against peers pursuing similar technology classes.
Who files at Regenerx's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- RED BOX Recorders
RED BOX RECORDERS LIMITED
5 patents
- REED Manufacturing
REED MANUFACTURING COMPANY
5 patents
- Reform Biologics
REFORM BIOLOGICS, LLC
5 patents
- Regenerative Medi…
REGENERATIVE MEDICAL SOLUTIONS, INC.
5 patents
- Rehau Construction
REHAU Construction LLC
5 patents
- Rehau-behr A/S
REHAU-BEHR A/S
5 patents
- REID Consulting G…
REID CONSULTING GROUP, INC.
5 patents
- REL
REL, INC.
5 patents
- Regenerx Biopharm… ◀
REGENERX BIOPHARMACEUTICALS, INC.
5 patents
What this shows Regenerx holds 5 patents at rank #49,962, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Regenerx
By rank, the assignees closest to #49,962 in granted patent volume.
- RED BOX Recorders Limited #49,958 · 5 patents
- REED Manufacturing Company #49,959 · 5 patents
- Reform Biologics, Llc #49,960 · 5 patents
- Regenerative Medical Solutions, Inc. #49,961 · 5 patents
- Rehau Construction Llc #49,963 · 5 patents
- Rehau-behr A/s #49,964 · 5 patents
- REID Consulting Group, Inc. #49,965 · 5 patents
- REL, Inc. #49,966 · 5 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Regenerx's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Regenerx's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
21 Top 93% higher than 7% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 20.0% |
| 2016 | 1 | 20.0% |
| 2017 | 2 | 40.0% |
| 2018 | 1 | 20.0% |
Which technologies does Regenerx Biopharmaceuticals, Inc. patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Regenerx Biopharmaceuticals, Inc. hold?
Regenerx Biopharmaceuticals, Inc. holds 5 US granted patents filed between 2015 and 2018, spanning 3 technology areas.
What is Regenerx Biopharmaceuticals, Inc.'s Innovation Score?
Regenerx Biopharmaceuticals, Inc. has an Innovation Score of 20.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Regenerx Biopharmaceuticals, Inc. focus on?
Regenerx Biopharmaceuticals, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 5 patents. The company has filed patents in 3 CPC subclasses total.
Is Regenerx Biopharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Regenerx Biopharmaceuticals, Inc.'s recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Regenerx Biopharmaceuticals, Inc.'s patents?
Regenerx Biopharmaceuticals, Inc.'s patents average 14.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the Regenerx Biopharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Regenerx's 5 grants land it in the top 93% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Regenerx ranks #49,962 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.